High Vista Strategies LLC Bellus Health Inc. Transaction History

High Vista Strategies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.14 - $8.53 $165,655 - $197,904	-23,201 Reduced 25.36%	68,292 $491,000
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $120,414 - $157,623	14,649 Added 19.06%	91,493 $752,000
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $362,296 - $485,760	40,480 Added 111.32%	76,844 $811,000
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $186,112 - $288,676	-28,810 Reduced 44.2%	36,364 $336,000
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $362,367 - $520,740	65,174 New	65,174 $448,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.